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Background: Patients with chronic aortic valve regurgitation (AR) causing left ventricular (LV) volume overload can
remain asymptomatic for many years despite having a severely dilated heart. The sudden development of heart
failure is not well understood but alterations of myocardial energy metabolism may be contributive. We studied the
evolution of LV energy metabolism in experimental AR.
Methods: LV glucose utilization was evaluated in vivo by positron emission tomography (microPET) scanning of
6-month AR rats. Sham-operated or AR rats (n = 10-30 animals/group) were evaluated 3, 6 or 9 months post-surgery.
We also tested treatment intervention in order to evaluate their impact on metabolism. AR rats (20 animals) were
trained on a treadmill 5 times a week for 9 months and another group of rats received a beta-blockade treatment
(carvedilol) for 6 months.
Results: MicroPET revealed an abnormal increase in glucose consumption in the LV free wall of AR rats at 6 months.
On the other hand, fatty acid beta-oxidation was significantly reduced compared to sham control rats 6 months post
AR induction. A significant decrease in citrate synthase and complex 1 activity suggested that mitochondrial oxidative
phosphorylation was also affected maybe as soon as 3 months post-AR.
Moderate intensity endurance training starting 2 weeks post-AR was able to partially normalize the activity of various
myocardial enzymes implicated in energy metabolism. The same was true for the AR rats treated with carvedilol
(30 mg/kg/d). Responses to these interventions were different at the level of gene expression. We measured
mRNA levels of a number of genes implicated in the transport of energy substrates and we observed that
training did not reverse the general down-regulation of these genes in AR rats whereas carvedilol normalized
the expression of most of them.
Conclusion: This study shows that myocardial energy metabolism remodeling taking place in the dilated left ventricle
submitted to severe volume overload from AR can be partially avoided by exercise or beta-blockade in rats.* Correspondence: jacques.couet@med.ulaval.ca
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The role of impaired myocardial energetics in the devel-
opment and progression of heart failure (HF) seems to
be central [1]. The energy-depletion theory of HF is not
new and a multitude of recent studies have provided
solid evidence that myocardial metabolism is strongly af-
fected in humans as well as in many animal models of
left ventricular hypertrophy and HF [1-3]. Both systolic
and diastolic functions seem to be intimately affected by
impaired myocardial energetics [4-8].
Alterations of myocardial metabolism caused by chronic
valve disease such as aortic regurgitation (AR) are unclear
and have not been studied like the ones caused by pres-
sure overload or ischemia [9-19]. Chronic AR is usually
well tolerated for many years before HF occurs. AR pa-
tients develop severely dilated and hypertrophied hearts
but remain in a clinical pre-HF state with a normal LV
ejection fraction for long periods of time [20]. The reason
why they suddenly progress towards symptoms and HF
after this long stable period is not well understood. There
is currently no treatment proven effective to decrease AR
related morbidity-mortality or delay the evolution towards
HF in humans [21]. The only solution available for now
remains valve replacement surgery when the left ventricle
becomes too dilated, systolic indices progressively de-
crease or when symptoms occur. Over the years, we have
showed that treatment targeting the renin-angiotensin-
aldosterone or the adrenergic systems can help reduce LH
hypertrophy, maintain cardiac function and improve sur-
vival in a rat model of chronic AR [22-25]. We did observe
a similar effect by non-pharmaceutical strategy i.e. moder-
ate endurance training [26].
We suggested that AR left ventricles with severe ec-
centric hypertrophy suffer from significant myocardial
metabolic impairment even before systolic dysfunction
becomes apparent and observed that as early as 8 weeks
post-AR myocardial energy substrate preference was al-
tered and a switch toward increased glucose utilization
was observed [27].
Here, we studied the long-term alteration in LV en-
ergy metabolism associated with chronic volume over-
load caused by severe AR in Wistar rats. We show that
treatments (training and beta-blockade) that reduce LV
dilatation and help maintain function are also associated
with a normalization of the energy metabolism.
Methods
Animals
Six groups of Wistar male rats (350–375 g) were studied
for either 90, 180 or 270 days. For each end-point time,
the animals were divided in two groups: sham-operated
animals (sham) or surgically induced AR. All groups con-
sisted of 15 animals with the exception of the 270-day
AR group consisting of 30 animals. An additional group(n = 10) of young healthy rats served as controls. For the
μPET study, eight additional animals (4 shams and 4 AR)
were studied 6 months after surgery. For endurance train-
ing protocol, a group of 20 animals were exercised 5 days/
week for 270 days on a motorized treadmill with a slope
of 10°. The duration and the intensity increased progres-
sively during the first 8 weeks until the animals were run-
ning for 30 minutes at 20 m/min as previously described
[26]. The influence of beta-blockade was tested using car-
vedilol in four groups of male Wistar rats (15 animals/
group): sham and AR animals receiving or not carvedilol
(30 mg/kg/d in drinking water). Training or carvedilol
were started two weeks post-surgery for six months. The
protocol was approved by the Université Laval’s Animal
Protection Committee and followed the recommendations
of the Canadian Council on Laboratory Animal Care. The
animal PET imaging protocol was approved by the Animal
Ethics Committee of the Faculty of Medicine of the Uni-
versité de Sherbrooke. Severe AR was induced by retro-
grade puncture of the aortic valve leaflets as previously
described [28]. At the end of the protocols, surviving ani-
mals were sacrificed, hearts were quickly dissected and all
cardiac chambers were weighed. LV was snap-frozen in li-
quid nitrogen and kept at −80°C for further analysis. All
sacrifices were scheduled at similar times of the day to
avoid circadian variations.
Echocardiography
A complete M-Mode, 2D and Doppler echocardiogram
was performed on the animals under 1.5% inhaled isoflur-
ane anesthesia using a 12 MHz probe with a Sonos 5500
echograph (Philips Medical Imaging, Andover, MA) im-
mediately before and during surgery, after 2 weeks, 3, 6
and 9 months as previously described [26].
Small animal PET protocol
Imaging experiments and data analysis were performed es-
sentially as described before [29-32] on a LabPET™ avalanche
photodiode-based small animal PET scanner (Gamma
Medica, Northridge, CA) at the Sherbrooke Molecular
Imaging Centre. [18F]-fluorodeoxyglucose ([18F]-FDG) (30–
40 MBq, in 0.3 ml plus 0.1 ml flush of 0.9% NaCl) was
injected via the caudal vein over 30 s. A 45-min dynamic
PET data acquisition followed by a 15-min static acquisi-
tion was done to determine glucose utilization [myocardial
metabolic rate of glucose (MMRG)] using multicompart-
mental analysis as previously described [32,33]. The static
scan served to draw regions-of-interest (ROIs) on each seg-
ment of the LV wall. Blood samples were taken before and
after the scans to determine an average blood glucose level.
Analysis of mRNA accumulation by quantitative RT-PCR
The analysis of LV mRNA levels by quantitative RT-PCR
has been described in details elsewhere [26].
Lachance et al. BMC Cardiovascular Disorders 2014, 14:190 Page 3 of 11
http://www.biomedcentral.com/1471-2261/14/190Enzyme activity determination
Enzyme activity assays are described in details in the sup-
plementary section (Additional file 1, Methods) [25,27,34].
Statistical analysis
Results are presented as mean ± SEM unless specified
otherwise. Inter-group comparisons were done using
Student’s t-test or Mann–Whitney t-test for PET proto-
col. One-way or two-way ANOVA were also used for
the analysis of data when required. Statistical signifi-
cance was set at a p < 0.05. Data and statistical analysisFigure 1 Evolution of LV remodeling as evaluated by echocardiogra
regurgitation in Wistar rats. LV dimensions, ejection fraction (EF), heart ra
Doppler mitral annular early diastolic velocity (E/Ea ratio) were evaluated thro
sham-operated animals (sham: white circles or bars) and AR rats (AR: black cir
Body weight was also recorded at the time of echocardiography. Left ventricu
(EDP) were evaluated by direct LV catheterization prior euthanasia. LV weight
wall thickness. Results are reported in as mean ± SEM (n = 10–15 per group). *were performed using Graph Pad Prism version 6.04 for
Windows, Graph Pad Software (San Diego, CA).
Results
All sham-operated animals were alive at the end of the
protocol. After 3, 6 and 9 months, 14/15, 12/15 and 14/30
animals were still alive in the AR groups, respectively. As
illustrated in Figure 1, no differences in body weight were
observed between the sham and AR groups. Overall
growth was similar between groups (similar tibial lengths,
results not shown). LV wet tissue weights were significantlyphy in experimental volume overload from severe aortic valve
te (HR), stroke volume (SV) and ratio of early transmitral velocity to tissue
ughout the course of the protocol as assessed by echocardiography in
cles or bars) at the beginning of the protocol, after 90, 180 and 270 days.
lar wet tissue weight was evaluated at sacrifice. End-diastolic pressures
, EDD: end-diastolic diameter, ESD: end-systolic diameter, Septum: septal
p < 0.05, **p < 0.01 and ***p < 0.001 between sham and AR groups.
Lachance et al. BMC Cardiovascular Disorders 2014, 14:190 Page 4 of 11
http://www.biomedcentral.com/1471-2261/14/190increased in the AR groups compared to controls and this
increase was steady over the 9 month period.
Echocardiographic data
The echocardiographic data from all study groups are
also presented in Figure 1. End-diastolic (EDD) and end-
systolic diameters (ESD) sharply increase during the first
3 months and continue to increase but at a slower pace
thereafter. AR animals have a lower ejection fraction
than normal sham animals. Ejection fraction slowly de-
creases over the 9 months but it still remains within
what is considered a normal range (above 60%). The end
result after 9 months of chronic severe AR is a severely
dilated ventricle with eccentric hypertrophy and rela-
tively preserved ejection fraction. AR animals have as
expected an increased stroke volume compared to
normal sham animals whereas their heart rate is slightly
diminished. Diastolic echocardiographic parameters
were also measured. AR animals had a significantly
higher E/Ea ratio than sham animals suggesting in-
creased left ventricular end-diastolic pressures. This
correlated well with the invasive LV end-diastolic pres-
sures (EDP) measurements that were also increased in the
AR groups.Figure 2 Evaluation by real-time quantitative RT-PCR of the LV mRNA
between sham and AR groups. Sham (sham-operated animals) at 90 days p
natriuretic peptide; αMHC, myosin heavy chain alpha; βMHC, myosin hMarkers of hypertrophy and extracellular matrix remodeling
The relative gene expression of both the alpha and beta
forms of myosin heavy chains was modified in AR ani-
mals in which the alpha/beta ratio was strongly reduced
(Figure 2). As expected, ANP gene expression was elevated
in AR animals.
Myocardial glucose consumption
Micro-PET imaging was used to investigate how glucose
consumption was altered in vivo in AR rats after 6
months of severe volume overload. Regional myocardial
metabolic rate of glucose (MMRG) was estimated from
the dynamic uptake of [18F]-FDG after intravenous bolus
injection using μPET. As illustrated in Figure 3, MMRG
was increased in AR myocardium and this increase was
preferentially located to the LV free wall (anterior and
lateral).
Myocardial metabolic enzymes
We measured enzymatic activity levels in LV crude ho-
mogenates (Figure 4). The HADH (hydroxyacyl-Coenzyme
A dehydrogenase) responsible for fatty acid β-oxidation
was less active in the AR group after 9 months compared
to sham animals. Normal aging also reduced HADHlevels of genes related to LV hypertrophy. *p < 0.05 and ***p < 0.001
ost-surgery group mRNA levels were normalized to 1. ANP, atrial
eavy chain beta; α/β: ratio of the two MCH forms.
Figure 3 In vivo glucose uptake by the left ventricle of AR and
sham rats as evaluated by micro positron emission tomography
(μPET). Myocardial metabolic rate of glucose (MMRG) was evaluated
as described in the Material and Methods section for each segment
of the LV wall as schematized in the bottom right of the figure.
Regional MMRG evaluation was realized in four different animals
per group and results were expressed as the mean ± SEM. *p < 0.05
between sham and AR groups. Sept: septal wall, Ant: anterior wall,
Lat: lateral wall and Inf: inferior wall. At the right of the column
graph, representative transaxial μPET scan images after injection
of [18F]-FDG are illustrated.
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than in chronic AR. Normal aging was accompanied by a
steady decrease in the activity level of the glycolytic en-
zyme phosphofructokinase (PFK) whereas it remained
stable in AR animals over the 9 month follow-up. This re-
sulted in a higher PFK activity level in AR animals after 9
months compared to age-matched sham animals. The
entry of acetyl-CoA in the citric acid cycle is catalyzed in
the mitochondria by the citrate synthase (CS). Again, nor-
mal aging was accompanied by a decrease in CS activity
levels. CS activity levels were however significantly lower
in AR animals after 3, 6 and 9 months when compared to
aged-matched sham animals. The first step of glycolysis is
catalyzed by the hexokinase (HK). HK activity levels were
significantly increased in all AR animals compared to the
shams after 9 months. On the other hand, the first step in
the electron transfer chain (mitochondrial ETC. complex
1) was strongly reduced in AR rats compared to sham
after 9 months while lactate dehydrogenase levels were
not significantly changed.
Endurance training can help normalize myocardial
metabolic enzymes
In order to evaluate if some alterations of the myocardial
energy metabolism could be reversed, we tested the impact
of moderate endurance training we previously showed to
improve the condition of chronic AR rats. AR rats werethus submitted to moderate intensity endurance training
on a treadmill (up to 20 m/s for 30 minutes) for a period
of 9 months. Of the 20 animals, 14 survived the entire
protocol. As illustrated in Figure 5, endurance training did
not reduce the heart hypertrophy in AR animals although
a trend was observed. Levels of enzymatic activity were
normalized for the HADH, CPT, PFK and CS suggesting
an improvement of the myocardial metabolic profile asso-
ciated with exercise.
Endurance training does not reverse the down-regulation
of genes associated with energy metabolism in AR
The results of the 9 month AR gene expression levels of
various enzymes and transporters related to fatty acid and
glucose metabolism in the myocardium compared to age-
matched sham animals as well as the effects of training are
summarized in Figure 6. FAT/CD36 gene expression (re-
sponsible for fatty acids transport into the cell) as well as
those of CPT1b and CPT2 (responsible for the entry of
fatty acids in the mitochondrion), were all decreased in AR
animals. Glucose transporters (GLUT) 1 and 4 mediate
glucose entry in the cell. GLUT4 mRNA expression levels
were decreased by about 25% in AR animals whereas
mRNA levels encoding for GLUT1 remained unchanged.
The formation of acetyl-CoA from pyruvate is catalyzed by
the pyruvate dehydrogenase complex. We evaluated the
gene expression of one member of this complex (PDH1α)
as well as one of its inhibitors (PDH kinase 4 or PDK4).
The expression of those two genes was significantly down-
regulated in AR animals. One main regulator of fatty acid
oxidation is the peroxisome proliferator-activated receptor
alpha (PPARα). PPARα mRNA levels were lower in AR
animals after 9 months. The mechanism by which PPARα
activates a mitochondrial biogenic response involves one
of its inducible co-activator: the peroxisome proliferator-
activated receptor gamma coactivator-1-alpha or PGC-1α.
The mRNA levels encoding for this gene was also mark-
edly reduced in our AR animals. The same was true for
the gene expression of the uncoupling protein 3 (UCP3).
We also evaluated ANT1 (adenine nucleotide translocase
1) which is known to facilitate the exchange of extra-
mitochondrial ADP with mitochondrial ATP. We ob-
served again a strong decrease in the expression of this
gene in the AR animals compared to the sham controls.
Training did not modulate gene expression in AR rats for
the molecules evaluated.
A six-month carvedilol treatment improves the energy
metabolism enzyme activity levels as well as the expression
profile of metabolic genes in AR rats (Figures 7 and 8).
At the end of the 6-month protocol, all sham-operated
treated or not with carvedilol were alive while 9/15 and
12/15 rats were still present in the AR-Veh and AR-Carv
groups, respectively. LV hypertrophy was present in both
AR groups but significantly less in the animals treated
Figure 4 (See legend on next page.)
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Figure 4 LV myocardial activity levels of enzymes implicated in fatty acid β-oxidation, glucose metabolism and mitochondrial energy
production in 9-month AR rats and relative evolution over time. HADH (hydroxyacyl-Coenzyme A dehydrogenase; A), PFK (phosphofructokinase;
B), citrate synthase (CS; C) enzymatic activities were measured in LV homogenates from at least 10 animals in each group as described in the
Methods. Hexokinase (HK; D), complex 1 (ETC. complex 1, rotenone-sensitive activity; E) and LDH (lactate dehydrogenase (F) activities were
measured in LV homogenates from 10 270-day animals. Results are reported relative to activity level measured in 90-day sham rats (A, B and C)
or in μmoles/min/mg of tissue (D, E, and F) or. *p < 0.05, **p < 0.01 and ***p < 0.001 between sham and AR groups.
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size of cardiac myocytes as evaluated in LV sections
(Additional file 1: Figure S1).
As illustrated in Figure 7, the carvedilol treatment
partially reversed the changes in HADH, hexokinase,
citrate synthase and complex 1 associated with eccentric
LHV in AR rats.
The same was true for the LV mRNA levels of a number
of genes associated with energy metabolism where the gen-
eral down-regulation was mostly reversed by carvedilol.
Discussion
Factors influencing the development and evolution of
LV remodelling in AR are poorly understood. Here, we
provide a longitudinal study focusing on myocardial en-
ergy metabolism in the LV of rats with chronic severe AR.
The heart is in a constant need of energy substrates
since it does not maintain significant reserve [1]. The
myocardial energetic machinery is complex and can beFigure 5 Moderate endurance training (tr) helps normalize activity le
9-month AR rats. Indexed (i) heart weight was corrected for the tibial len
PFK (phosphofructokinase), citrate synthase (CS) and complex 1 enzymatic ac
Results are expressed as mean ± SEM (n = 10/group) in μmoles/min/mg of tis
¶p < 0.05 between AR and AR-tr groups.affected at many interacting levels including: substrate
utilization/preference, oxidative energy production in the
mitochondria, energy transport and consumption by the
contractile myofibrils [35].
Our experimental model causes severe LV dilatation.
Despite the presence of important hypertrophy in this rat
model, HF remains a late occurring event as seen in
humans [36]. As we have previously reported, the majority
of AR rats have a systolic function within normal range
(ejection fraction > 60%, normal dP/dt+) even after 9 months
[26]. Diastolic abnormalities become clearly evident as
soon as 2 or 3 months after AR induction [34,37].
As reported by others in models of LV concentric
hypertrophy and of HF, we too observed a shift in the ratio
of the gene expression of myosin heavy chains α and β
in AR rats. This also occurs but much less, with normal
aging [38]. This shift can significantly affect the ener-
getic efficiency of the heart and could point towards an
imminent shift towards HF.vels of enzymes implicated in the LV energy metabolism in
gth. HADH (hydroxyacyl-Coenzyme A dehydrogenase), HK (hexokinase)
tivities were measured in LV homogenates as described in the Methods.
sue. *p < 0.05, **p < 0.01 and ***p < 0.001 between sham and AR and
Figure 6 Evaluation by real-time quantitative RT-PCR of the
LV mRNA levels of 11 genes related to cardiac metabolism in
9-month rats and impact of endurance training. Results are
reported in arbitrary units as mean ± SEM (n = 15/gr). Levels in sham
animals were fixed to 1. FAT/CD36: fatty acid transporter/CD antigen
36, CPT1b: carnitine palmitoyltransferase 1b and CPT2: carnitine
palmitoyltransferase 2, Glut1: glucose transporter 1, Glut4: glucose
transporter 4, PDH1a: pyruvate dehydrogenase 1 alpha and PDK4:
pyruvate dehydrogenase kinase 4, PPARα: peroxisome proliferator
activator receptor alpha, PGC-1α: Peroxisome proliferator-activated
receptor gamma coactivator-1-alpha, UCP3: uncoupling protein 3
and ANT: adenine nucleotide translocase. P values are indicated
above each bar compared to sham controls. ¶p < 0.05 between AR
and AR-tr groups.
Figure 7 Beta-blocker carvedilol treatment helps normalize
activity levels of enzymes implicated in the LV energy
metabolism in 6-month AR rats. Indexed (i) heart weight was
corrected for the tibial length. HADH (hydroxyacyl-Coenzyme A
dehydrogenase), HK (hexokinase) PFK (phosphofructokinase), citrate
synthase (CS) and carnitine palmitoyl transferase (CPT) enzymatic
activities were measured in LV homogenates as described in the
Methods. Results are expressed as mean ± SEM (n = 9-12/group)
in μmoles/min/mg of tissue. *p < 0.05, **p < 0.01 and ***p < 0.001
between sham and AR groups and ¶p < 0.05 between AR and
AR-Carv groups.
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LV myocardium of AR rats increased its glucose con-
sumption. This increase seems to be more pronounced
in the LV free wall mostly in the lateral and anterior por-
tions. It could be suggested that dilation may not be
homogeneous through the LV was and that the observed
metabolic changes in the LV myocardium may reflect
this. We already observed the opposite situation in the
AR rat where fatty acid uptake was reduced in the same
LV region where we now observe an increase in glucose
uptake [25]. Concentric LV hypertrophy is associated with
a shift in substrate preference from free fatty acids to glu-
cose [35]. Our μPET results confirm this for our animals
in vivo with eccentric VO LVH.
We also described the impact of normal aging on the
levels of enzymatic activity related to myocardial metab-
olism. We detected a significant loss of myocardial activ-
ity for three central metabolic enzymes (HADH, CS and
PFK) due to normal aging. The activity levels of these
enzymes decreased by at least 25% in the last six months
of the protocol. It is possible though that these changes
reflect a progression from a stage of global body growth at
a younger age to the more stable adult stage. Adding AR
amplified this effect on HADH and CS activities. This sug-
gests that fatty acid oxidation is further impaired in the
late stage of AR and that the total mitochondrial oxidative
capacity of the myocardium may then be less than normal
[10]. On the other hand, PFK activity remained stable in
the hearts of AR animals suggesting a shift towards
glucose utilization as previously seen in concentric LV
hypertrophy and HF [39]. μPET imaging also confirmedthis hypothesis. Our data show a decrease in fatty acid
transport-related Fat/CD36 in the animals with AR.
Carnitine palmitoyl-transferase gene expression and en-
zymatic activity was also decreased. These observations
are consistent with data published in other models of
LVH [11,40]. The mitochondrial energetic machinery also
seems to be affected by the LV volume overload as shown
not only by the decrease in CS activity but also by the
strong decrease in the activity of the ETC. complex I in
9-month AR animals. These mitochondrial enzymatic
abnormalities could result in myocardial energy starving
either in the basal state or in response to an acute stress
Figure 8 Carvedilol reverses down-regulation of genes implicated in cardiac energy metabolism in 6-month AR rats. Results are reported
in arbitrary units as mean ± SEM (n = 15/gr). Levels in sham animals were fixed to 1. FAT/CD36: fatty acid transporter/CD antigen 36, Glut1: glucose
transporter 1, Glut4: glucose transporter 4, PDH1a: pyruvate dehydrogenase 1 alpha and PDK4: pyruvate dehydrogenase kinase 4, PPARα: peroxisome
proliferator activator receptor alpha, PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator-1-alpha, UCP3: uncoupling
protein 3 and ANT: adenine nucleotide translocase. P values are indicated above each bar compared to sham controls. ¶p < 0.05 between
AR and AR-tr groups.
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ported that VO could induce an inappropriate response to
various stresses in two different animal models during
the compensated phase of the disease [16,19]. The down-
regulation of ANT1 is another clue pointing towards an
abnormal exportation of ATP from the mitochondrion
[41] which seems to be seriously impaired in our AR ani-
mals after 9 months. The gene expression of PDH1α which
is responsible for pyruvate entry into the mitochondria was
reduced in AR animals after 9 months compared to nor-
mal age-matched controls. Myocardial energetic status at
this late stage of the disease in our AR animals probably
shares similarities to the one seen in established HF
even if systolic function remains in the normal range in
our animals.
This study also clearly shows that regular exercise has
beneficial effects on the myocardial energetic machinery
in this animal model of volume overload cardiomyop-
athy even before systolic heart failure occurs. These ef-
fects were detectable on enzymes and pathways related
to fatty acid oxidation and glycolytic capacity as well as
to mitochondrial efficiency. The benefits of exercise on LV
remodeling, diastolic function and survival we have re-
cently reported could therefore be in part related to im-
provement in myocardial energetics [26]. One possible
mechanism may be via the activation of the IGF1/PI3K/
Akt pathway by exercise which can activate survival path-
ways in cardiac myocytes [42,43].
We also observed an improvement of myocardial ener-
getics in AR animals treated with the beta-blocker, car-
vedilol. We had reported that beta-blockade using either
metoprolol or carvedilol can reduce the extent of LV
hypertrophy development in the rat AR model [23,36].
The benefits in maintaining systolic function were similarto those observed in endurance-trained animals [26]. It is
interesting to observe that although the effects of beta-
blockade and exercise were similar at normalizing meta-
bolic enzyme activities, carvedilol treatment also restored
gene expression of a number of proteins implicated in the
control of substrate uptake and metabolism. This suggests
that similarities and differences exist between the mecha-
nisms of action of exercise and beta-blockade. Another
possibility is that by a better control of LVH develop-
ment by carvedilol, many parameters may remain in the
normal range.
Limitations
In this study, we used a range of techniques to evaluate
myocardial metabolism in AR rats to demonstrate that
substrate preference as well as general energy metabolism
is modified in this model and that endurance training and
beta-blockade can partially reverse these changes. Obvi-
ously, our study can only offer an incomplete portrait of
the complex metabolic changes taken place in the myocar-
dium submitted to severe and chronic volume overload.
Enzyme activity determinations and gene expression stud-
ies made here cannot encompass the wide array of modifi-
cation in energetics in the hypertrophied myocardium.
More thorough studies using μPET in vivo, isolated heart
or mitochondria studies could offer supplementary infor-
mation to better describe these changes.
Conclusion
Our results clearly show that the myocardium with chronic
VO suffers from a significant metabolic stress and develops
over time important metabolic abnormalities.
These findings provide for the first time new longitu-
dinal data which may improve our view of the dilated
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comfortable to follow those patients without any interven-
tion for many years, simply waiting for the LV to become
too dilated, for the occurrence of symptoms or until
systolic function begins to fall. Based on our findings,
we suggest that those volume overloaded hearts develop
severe metabolic abnormalities even when systolic func-
tion seems preserved. Focusing on myocardial metabolism
by various interventions such as targeted drugs, specific
diets or exercise may help this metabolically stressed myo-
cardium to improve energy production and maybe prolong
the pre-heart failure state significantly. Further studies will
be needed to confirm this hypothesis.
Additional file
Additional file 1: Supplemental methods and data. This file contains
more detailed methods for the enzymatic assays as well as references. In
addition, Figure S1. is a complement of data for the carvedilol study of
Figures 7 and 8 in the manuscript.
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